losartan has been researched along with Cystic Fibrosis of Pancreas in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, MD | 2 |
| Bengtson, CD | 1 |
| Yoshida, M | 2 |
| Niloy, AJ | 1 |
| Dennis, JS | 2 |
| Baumlin, N | 2 |
| Salathe, M | 2 |
| Polineni, D | 1 |
| Salathe, SF | 1 |
| David, JK | 1 |
| Peloquin, CA | 1 |
| Wanner, A | 1 |
| Sailland, J | 1 |
| Whitney, P | 1 |
| Horrigan, FT | 1 |
| Sabater, JR | 1 |
| Abraham, WM | 1 |
| Bonfield, TL | 1 |
| Chan, HC | 1 |
| Law, SH | 1 |
| Leung, PS | 1 |
| Fu, LX | 1 |
| Wong, PY | 1 |
4 other studies available for losartan and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Losartan ameliorates TGF-β1-induced CFTR dysfunction and improves correction by cystic fibrosis modulator therapies.
Topics: Benzodioxoles; Cyclooxygenase 2; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulato | 2022 |
Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Bronchi; Cells, Cultured; Cystic Fibrosis; Disease | 2020 |
Preclinical Modeling for Therapeutic Development in Cystic Fibrosis.
Topics: Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Inflammation; Losartan | 2020 |
Angiotensin II receptor type I-regulated anion secretion in cystic fibrosis pancreatic duct cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Angiotensin II; Angiotensin Receptor Antagonists; | 1997 |